Sign up online today & collaborate
or click here to find out more
Consilium Strategic Communications (“Consilium”), a global leader in healthcare strategic communications, announces that its client, Arix Bioscience plc (“Arix”), has successfully raised £100 million ahead of its proposed admission to the Main Market of the London Stock Exchange.
Arix Bioscience announced on 17 February 2017 that it had raised a total of £100 million by way of an oversubscribed issue of New Ordinary Shares from a broad range of investors including Woodford Investment Management (acting on behalf of its fund clients) and pharmaceutical companies UCB S.A. and Takeda Pharmaceuticals (working through its ventures group, Takeda Ventures, Inc.). Arix Bioscience is expected to begin trading on the Main Market of the London Stock Exchange at 8:00am GMT on 22 February, under the ticker “ARIX”, with a market capitalisation of approximately £187 million.
Arix Bioscience is a global healthcare and life science company, which sources, finances and develops high quality healthcare and life science businesses and is focused on generating value from the development and commercialisation of innovative technologies and discoveries. Through its sourcing platforms including but not limited to access to privileged agreements with leading universities and other academic and research institutions, Arix Bioscience has acquired interests in Artios Pharma, Autolus, Depixus, BioMotiv, Verona Pharma and Optikira.
The Consilium Strategic Communications team, comprising Mary-Jane Elliott, Ivar Milligan, Jessica Hodgson, Melissa Gardiner and Cameron Standage, will continue to advise Arix Bioscience on its international financial PR and investor relations strategies as a publicly listed company.
Joe Anderson, Chief Executive Officer of Arix Bioscience plc, said: “Consilium’s highly experienced team has provided us with excellent advice throughout the IPO process. They have acted with an extremely high level of professionalism, focus and endurance that has been key to us getting this right. I am very excited at what Arix can achieve from here and am hugely grateful to Consilium for their ongoing support.”
Mary-Jane Elliott, Consilium Strategic Communications’ Managing Partner, said: “We are pleased to have played a key part in Arix Bioscience’s successful IPO and look forward to supporting the company as it now navigates life as a listed entity. The IPO was oversubscribed and we see this as a huge vote of confidence by international investors across the board in our international healthcare sector.”
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell / Chris Gardner
Tel: +44(0)20 3709 5700
Follow us on Twitter: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in providing trusted, healthcare-focused strategic IR and financial PR counsel to corporations, Boards, senior decision makers and executives. From offices in Europe and USA, Consilium Strategic Communications’ senior team provides cross-border comprehensive financial and corporate healthcare communications advice to some of the world’s most prominent corporations around-the-clock. For more information, please visit our website at www.consilium-comms.com